Effect of ularitide on cardiovascular mortality in acute heart failure

New England Journal of Medicine

Volumn 376, Issue 20, 2017, Pages 1956-1964

  Packer, M ^a   O'Connor, C ^c   McMurray, J J V ^d   Wittes, J ^e   Abraham, W T ^f   Anker, S D ^g   Dickstein, K ^h   Filippatos, G ⁱ   Holcomb, R ^j   Krum, H ^k   Maggioni, A P ^l   Mebazaa, A ^m   Peacock, W F ^b   Petrie, M C ^d   Ponikowski, P ⁿ   Ruschitzka, F ^o   Van Veldhuisen, D J ^q   Kowarski, L S ^e   Schactman, M ^e   Holzmeister, J ^o,p  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c INOVA HEART AND VASCULAR INSTITUTE   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e University of Iowa   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^h UNIVERSITY OF BERGEN   (Norway)

ⁱ UNIVERSITY OF ATHENS   (Greece)

^j Monash University ^*  (United States)

^k MONASH UNIVERSITY   (Australia)

^l ANMCO RESEARCH CENTER   (Italy)

^m APHP   (France)

ⁿ WROCLAW MEDICAL UNIVERSITY   (Poland)

^o UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^p Cardiorentis Ltd   (Switzerland)

^q UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; PLACEBO; TROPONIN T; URODILATIN; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL EVALUATION; CLINICAL OUTCOME; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EARLY INTERVENTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ACUTE DISEASE; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; HEART FAILURE; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; VERY ELDERLY;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ATRIAL NATRIURETIC FACTOR; BIOMARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIURETICS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPOTENSION; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; TROPONIN T;

EID: 85019818217     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1601895     Document Type: Article

References (37)

1. Blecker S, Paul M, Taksler G, Ogedegbe G, Katz S. Heart failure-associated hospitalizations in the United States. J Am Coll Cardiol 2013;61:1259-67.
2. Peacock WF IV, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008;358:2117-26.
3. Felker GM, Mentz RJ, Teerlink JR, et al. Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. Eur J Heart Fail 2015;17:1262-70.
4. Drexler B, Heinisch C, Balmelli C, et al. Quantifying cardiac hemodynamic stress and cardiomyocyte damage in ischemic and nonischemic acute heart failure. Circ Heart Fail 2012;5:17-24.
5. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007;116:1482-7.
6. Fonarow GC, Peacock WF, Horwich TB, et al. Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. Am J Cardiol 2008;101:231-7.
7. Scirica BM, Sabatine MS, Jarolim P, et al. Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. Eur Heart J 2011;32:697-705.
8. Heestermans T, van 't Hof AW, ten Berg JM, et al. The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy. Am Heart J 2010;160:1079-84.
9. Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013;61:196-206.
10. Maisel AS, Peacock WF, McMullin N, et al. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. J Am Coll Cardiol 2008;52:534-40.
11. Peacock WF, Emerman C, Costanzo MR, Diercks DB, Lopatin M, Fonarow GC. Early vasoactive drugs improve heart failure outcomes. Congest Heart Fail 2009;15:256-64.
12. Wong YW, Mentz RJ, Felker GM, et al. Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. Eur J Heart Fail 2016;18:684-92.
13. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-200.
14. Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29-39.
15. Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 2013;1:103-11.
16. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541-7.
17. Packer M, Holcomb R, Abraham WT, et al. Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. Eur J Heart Fail 2016November 13 (Epub ahead of print).
18. Mitrovic V, Lüss H, Nitsche K, et al. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. Am Heart J 2005;150:1239.
19. Mitrovic V, Seferovic PM, Simeunovic D, et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006;27:2823-32.
20. Packer M. Development and evolution of a hierarchical clinical composite endpoint for the evaluation of drugs and devices for acute and chronic heart failure: a 20-year perspective. Circulation 2016;134:1664-78.
21. Anker SD, Ponikowski P, Mitrovic V, Peacock WF, Filippatos G. Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J 2015;36:715-23.
22. van der Meer P, Postmus D, Ponikowski P, et al. The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. J Am Coll Cardiol 2013;61:1973-81.
23. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010;122:265-72.
24. Davila C, Reyentovich A, Katz SD. Clinical correlates of hemoconcentration during hospitalization for acute decompensated heart failure. J Card Fail 2011;17:1018-22.
25. Cotter G, Metra M, Weatherley BD, et al. Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure - association with signs and symptoms, hospitalization duration, and 60-day outcomes. Cardiology 2010;115:29-36.
26. Butler J, Gheorghiade M, Kelkar A, et al. In-hospital worsening heart failure. Eur J Heart Fail 2015;17:1104-13.
27. Felker GM, Hasselblad V, Tang WH, et al. Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. Eur J Heart Fail 2012;14:1257-64.
28. DeVore AD, Greiner MA, Sharma PP, et al. Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2016;178:198-205.
29. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32-43.
30. McMurray JJ, Teerlink JR, Cotter G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007;298:2009-19.
31. 1-receptor antagonist, in acute heart failure. N Engl J Med 2010;363:1419-28.
32. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297:1332-43.
33. Metra M, Ponikowski P, Cotter G, et al. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. Eur Heart J 2013;34:3128-36.
34. Breidthardt T, Noveanu M, Potocki M, et al. Impact of a high-dose nitrate strategy on cardiac stress in acute heart failure: a pilot study. J Intern Med 2010;267:322-30.
35. Novartis heart drug portfolio hit by failed serelaxin study. Reuters, March 22, 2017 (http://www.reuters.com/article/us-novartis-heart-idUSKBN16T0QG).
36. Patel PA, Heizer G, O'Connor CM, et al. Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF. Circ Heart Fail 2014;7:918-25.
37. FDA briefing document:Cardiovascular and Renal Drugs Advisory Committee meeting, March 27, 2014 (http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM390443.pdf).